methyl 6-dimethoxymethylnicotinate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: methyl 6-dimethoxymethylnicotinate
• 英文别名: methyl 2-(Dimethoxymethyl)pyridine-5-carboxylate；methyl 6-(dimethoxymethyl)pyridine-3-carboxylate
• 化学式: C₁₀H₁₃NO₄
• 分子量: 211.218
• InChiKey: LCKFKYJFOMCTRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  57.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 6-dimethoxymethylnicotinate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 6-二甲氧基甲基烟酸钠盐
  参考文献：
  名称：

  钠链作为核心纳米线，用于从功能化的烟酸及其钠盐凝胶化有机溶剂。

  摘要：

  描述了一种由取代的烟酸及其钠盐的混合物形成的新型金属有机胶凝剂。烟酸在6-位被乙缩醛官能团取代。1：1混合物的晶体结构表明，钠原子在无限链中排列，氢键合的两个有机单元形成了潜在的三核配体，该配体包裹了金属核，从而形成了管状结构。发现这些一维晶体自发地使二氯甲烷凝胶化，并提供具有高耐热性的吡啶凝胶。通过几种分析技术研究了凝胶的形成，包括差示扫描量热法，TEM，冷冻断裂电子显微镜（FFEM），红外光谱和X射线衍射，并且被发现是由一维材料的膨胀引起的。FFEM和粉末X射线衍射表明，钠链以高度压缩的状态缔合成凝胶内部的分层结构。在不破坏凝胶的情况下，通过扩散用染料例如二甲苯氰，甲基黄和溴百里酚蓝对这些坚固的凝胶进行掺杂是可行的。

  DOI：

  10.1002/chem.200700660
• 作为产物：
  描述：

  6-甲基烟酸甲酯 在 甲酸 、 碘 、 三氟乙酸 作用下， 以 二甲基亚砜 为溶剂， 反应 8.0h， 生成 methyl 6-dimethoxymethylnicotinate
  参考文献：
  名称：

  SALT FORM AND CRYSTAL FORM SERVING AS FGFR AND VEGFR INHIBITOR COMPOUNDS, AND PREPARATION METHOD THEREFOR

  摘要：

  本发明公开了一种作为FGFR和VEGFR抑制剂化合物的盐形和晶形，其制备方法以及医药用途。

  公开号：

  US20200361913A1

文献信息

• New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040242572A1

  公开（公告）日：2004-12-02

  The present invention relates to carboxamide compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 , R 2 , R 3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及具有通式I的羧酰胺化合物 1 其中，A、B、W、X、Y、Z、R 1 、R 2 、R 3 和k的含义如权利要求1中所述。此外，本发明还涉及制备上述羧酰胺的方法以及含有至少一种根据本发明的羧酰胺的药物组合物。由于它们对MCH受体的拮抗活性，根据本发明的药物组合物适合用于治疗代谢紊乱和/或饮食紊乱，特别是肥胖症、厌食症、暴食症、糖尿病。
• New organogelators based on cyclotriveratrylene platforms bearing 2-dimethylacetal-5-carbonylpyridine fragments
  作者：David Bardelang、Franck Camerel、Raymond Ziessel、Marc Schmutz、Michael J. Hannon

  DOI：10.1039/b712413a

  日期：——

  Gelators, compounds able to solidify solvents, and in particular hydrogelators are interesting soft materials. In this paper we have synthesized cyclotriveratrylene (CTV) platforms symmetrically end-substituted with pendent primary amines or nicotamic substituents. These non-amphiphilic structures induce self-assembly in a large variety of solvents forming robust and opaque gels. Cyclotriveratrylene gels have for the first time been formed and characterized using FT-IR and freeze fracture electron microscopy. Two hierarchical events are responsible for the gel structure. Individual fibres of 4–5 nm diameter are formed by aggregation of the functionalised CTV molecules. These fibres then further self-assemble into large ribbons several µm long and 20 to 40 nm wide. Within the ribbons the fine striations observed by FFEM are due to individual straight chains organized in a highly compacted state. Within the fibres the individual CTV molecules are held together by hydrogen bonding of the amide function as probed by infra-red spectroscopy.

  凝胶剂是一类能够使溶剂固化的化合物，特别是水凝胶剂，是有趣的软材料。在本文中，我们合成了对称末端取代有侧基的初级胺或尼古丁取代基的环三维紫烯（CTV）平台。这些非两亲性结构在多种溶剂中诱导自组装，形成坚固而不透明的凝胶。环三维紫烯凝胶首次使用傅里叶变换红外光谱（FT-IR）和冷冻断裂电子显微镜（FFEM）进行了表征。凝胶结构由两个层次的事件组成。直径为4–5纳米的单个纤维是通过功能化的CTV分子的聚集形成的。这些纤维进一步自组装成几微米长、20至40纳米宽的大带状结构。在带状结构内，FFEM观察到的细条纹是由于个别直链以高度压缩的状态组织在一起。在纤维内，个别的CTV分子通过酰胺功能的氢键结合在一起，这一点通过红外光谱得到了验证。
• Thiazolidinedione hypoglycemic agents
  申请人：Pfizer Inc.

  公开号：US05061717A1

  公开（公告）日：1991-10-29

  Hypoglycemic thiazolidine-2,4-dione derivatives of the formula ##STR1## wherein the dotted line represents a bond or no bond; A and B are each independently CH or N, with the proviso that when A or B is N, the other is CH; X is S, SO, SO.sub.2, CH.sub.2, CHOH or CO; n is 0 or 1; Y is CHR.sup.1 or NR.sup.2, with the proviso that when n is 1 and Y is NR.sup.2, X is SO.sub.2 or CO; Z is CHR.sup.3, CH.sub.2 CH.sub.2, CH.dbd.CH, ##STR2## OCH.sub.2, SCH.sub.2, SOCH.sub.2 or SO.sub.2 CH.sub.2 ; R, R.sup.1, R.sup.2 and R.sup.3 are each independently hydrogen or methyl; and X.sup.1 and X.sup.2 are each independently hydrogen, methyl, trifluoromethyl, phenyl, benzyl, hydroxy, methoxy, phenoxy, benzyloxy, bromo, chloro or fluoro; a pharmaceutically-acceptable cationic salt thereof; or a pharmaceutically-acceptable acid addition salt thereof when A or B is N.

  含有以下结构的低血糖噻唑烷-2,4-二酮衍生物的化学式为##STR1##其中虚线代表键或无键；A和B各自独立地为CH或N，但如果A或B为N，则另一个为CH；X为S、SO、SO.sub.2、CH.sub.2、CHOH或CO；n为0或1；Y为CHR.sup.1或NR.sup.2，但如果n为1且Y为NR.sup.2，则X为SO.sub.2或CO；Z为CHR.sup.3、CH.sub.2 CH.sub.2、CH.dbd.CH、##STR2##OCH.sub.2、SCH.sub.2、SOCH.sub.2或SO.sub.2 CH.sub.2；R、R.sup.1、R.sup.2和R.sup.3各自独立地为氢或甲基；X.sup.1和X.sup.2各自独立地为氢、甲基、三氟甲基、苯基、苄基、羟基、甲氧基、苯氧基、苄氧基、溴、氯或氟；其药学上可接受的阳离子盐；或在A或B为N时，其药学上可接受的酸加盐。
• VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS
  申请人：Harbin Zhenbao Pharmaceutical Co., Ltd.

  公开号：EP3333157A1

  公开（公告）日：2018-06-13

  FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

  提供了表皮生长因子受体（FGFR）和血管内皮生长因子受体（VEGFR）抑制剂，并特别公开了作为表皮生长因子受体（FGFR）和血管内皮生长因子受体（VEGFR）抑制剂的式(1)或式(II)所代表的化合物、其药学上可接受的盐或同系物。
• Vinyl compounds as FGFR and VEGFR inhibitors
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US10519133B2

  公开（公告）日：2019-12-31

  FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

  提供了表皮生长因子受体（FGFR）和血管内皮生长因子受体（VEGFR）抑制剂，并特别公开了作为表皮生长因子受体（FGFR）和血管内皮生长因子受体（VEGFR）抑制剂的式(1)或式(II)所代表的化合物、其药学上可接受的盐或同系物。